The Pan American Health Organization (PAHO) will provide countries throughout the Americas, including the Caribbean, with affordable access to the vaccine against respiratory syncytial virus (RSV) starting in the first quarter of 2025.
RSV is a leading cause of pediatric hospitalization and death from respiratory infections during the first six months of life.
PAHO announced that approximately 13 million children born in the region each year could benefit from this vaccination program when administered to pregnant women.
Following recommendations from PAHO’s Advisory Committee on Immunization (ACIP) in November 2023, the vaccine should be administered to pregnant women between 32 and 36 weeks of gestation. This timing is crucial, as maternal antibodies provide protection against RSV for approximately six months after birth – the period when infants face the highest risk of severe disease.
“This strategy ensures effective protection for the newborn and reduces the risk of preterm birth,” PAHO officials stated.
Currently, the World Health Organization (WHO) has approved only one vaccine for preventing RSV-related diseases in infants. Countries in the region can access this vaccine through PAHO beginning in 2025.
The initiative will be implemented through PAHO’s Regional Revolving Fund, a cooperative mechanism with over 40 years of experience. The Fund provides technical support and facilitates bulk purchasing of more than 60 quality biological products at affordable prices for participating nations.
